Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin + SOCP for Daraxonrasib-Induced Skin Toxicity in Pancreatic Cancer
NCT07895498Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2026
- Primary completion
- Oct 2028
- Countries
- 1
01
Overview
A Phase 2 trial of CHILD-IVITAB in Skin Toxicity, sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2026; status: recruiting.
02
Drugs
CHILD-IVITAB
03
Conditions
Skin Toxicity
Beyond the preview
Go deeper on NCT07895498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07895498.